]> 2026-04-12T02:29:45-07:00 Radiation via Monoclonal Antibodies 0 en Potential risks are present and may be comparable to or slightly less than traditional treatments, with concerns about toxicity under investigation 2025-01-18T08:25:22Z 2460693.8509491 Radiation via Monoclonal Antibodies 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations."] Radiation via Monoclonal Antibodies# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name